SCHEMBL26812870

SCHEMBL26812870

Cc1ccc(S(=O)(=O)Nc2nc(Oc3ccccc3F)cc(-c3ccccc3C(C)C)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.47
▸ LMNA P02545 3/20 0.41
▸ HTT P42858 2/20 0.41
▸ TSHR P16473 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ KMT2A Q03164 2/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ GAA P10253 3/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ BRD4 O60885 2/20 0.39
▸ PTPRC P08575 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ THRB P10828 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ SCN9A Q15858 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29567008 0.93 TDP1 (0.45) TDP1LMNAHTTTSHRSMN1; SMN2
SCHEMBL24309354 0.93 TDP1 (0.45) TDP1LMNAHTTTSHRSMN1; SMN2
SCHEMBL29566577 0.92 TDP1 (0.47) TDP1LMNAHTTTSHRSMN1; SMN2
SCHEMBL26812864 0.92 TDP1 (0.44) TDP1LMNAHTTTSHRKMT2A
SCHEMBL29567103 0.92 MAPT (0.47) TDP1LMNAHTTTSHRSMN1; SMN2
SCHEMBL26812772 0.92 TDP1 (0.47) TDP1LMNAHTTTSHRSMN1; SMN2
SCHEMBL26812759 0.92 MAPT (0.47) TDP1LMNAHTTTSHRSMN1; SMN2
SCHEMBL29566852 0.91 TDP1 (0.44) TDP1LMNAHTTTSHRSMN1; SMN2
SCHEMBL24310180 0.91 TDP1 (0.44) TDP1LMNAHTTTSHRSMN1; SMN2
SCHEMBL24310800 0.91 TDP1 (0.42) TDP1LMNAHTTTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B TDP1 4534/4885LMNA 4052/4885HTT 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback